ZO-1 Serum Levels as a Potential Biomarker for Psychotic Disorder

Basit Öğe Kaydı
dc.contributor.authorAydoğan Avşar, Pınar
dc.contributor.authorAkkuş, Merve
dc.date.accessioned2026-01-24T12:20:43Z
dc.date.available2026-01-24T12:20:43Z
dc.date.issued2024
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractObjective There are limited studies in the literature on the relationship between intestinal and blood-brain barrier permeability and the etiology of schizophrenia. We hypothesized that the difference in serum ZO-1 levels in patients with schizophrenia may affect the severity of the disease. The aim of this study was to investigate the role of changes in serum ZO-1 concentrations in the etiopathogenesis of patients with schizophrenia. Methods A total of 46 patients, 34 with schizophrenia, 12 with a first psychotic attack, and 37 healthy controls, were included in the study. Symptom severity was determined by applying the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Serum ZO-1 levels were measured from venous blood samples. Results Serum ZO-1 levels were higher in patients with psychotic disorder compared to healthy controls. There was no statistically significant difference between the groups in the first psychotic attack group and the schizophrenia patients. There was a statistically significant positive correlation between serum ZO-1 levels and Positive and Negative Syndrome Scale positive symptom score. Conclusions These findings regarding ZO-1 levels suggest that dysregulation of the blood-brain barrier in psychotic disorder may play a role in the etiology of the disorder. © Wolters Kluwer Health, Inc. All rights reserved.
dc.identifier.doi10.1097/WNF.0000000000000590
dc.identifier.endpage71
dc.identifier.issn0362-5664
dc.identifier.issue3
dc.identifier.pmid38743599
dc.identifier.scopus2-s2.0-85193207866
dc.identifier.scopusqualityQ3
dc.identifier.startpage67
dc.identifier.urihttps://doi.org/10.1097/WNF.0000000000000590
dc.identifier.urihttps://hdl.handle.net/20.500.12868/4534
dc.identifier.volume47
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofClinical Neuropharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20260121
dc.subjectblood-brain barrier
dc.subjectpsychotic disorder
dc.subjectZO-1
dc.titleZO-1 Serum Levels as a Potential Biomarker for Psychotic Disorder
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu